248 related articles for article (PubMed ID: 30552156)
1. Safety and Activity of Sorafenib in Addition to Vinflunine in Post-Platinum Metastatic Urothelial Carcinoma (Vinsor): Phase I Trial.
Shah CH; Pappot H; Agerbæk M; Holmsten K; Jäderling F; Yachnin J; Grybäck P; von der Maase H; Ullén A
Oncologist; 2019 Jun; 24(6):745-e213. PubMed ID: 30552156
[TBL] [Abstract][Full Text] [Related]
2. Vinflunine-gemcitabine versus vinflunine-carboplatin as first-line chemotherapy in cisplatin-unfit patients with advanced urothelial carcinoma: results of an international randomized phase II trial (JASINT1).
De Santis M; Wiechno PJ; Bellmunt J; Lucas C; Su WC; Albiges L; Lin CC; Senkus-Konefka E; Flechon A; Mourey L; Necchi A; Loidl WC; Retz MM; Vaissière N; Culine S
Ann Oncol; 2016 Mar; 27(3):449-54. PubMed ID: 26673352
[TBL] [Abstract][Full Text] [Related]
3. Vinflunine in Metastatic Urothelial Carcinoma of the Bladder in Progression after a Platinum-Containing Regimen.
De Luca R; Profita G; Vella M; Cicero G
Oncology; 2019; 97(6):341-347. PubMed ID: 31461721
[TBL] [Abstract][Full Text] [Related]
4. Combined treatment with pemetrexed and vinflunine in patients with metastatic urothelial cell carcinoma after prior platinum-containing chemotherapy - results of an exploratory phase I study.
Pappot H; von der Maase H; Ullén A; Agerbæk M;
Invest New Drugs; 2018 Aug; 36(4):615-618. PubMed ID: 29081023
[TBL] [Abstract][Full Text] [Related]
5. Vinflunine in platinum-pretreated patients with locally advanced or metastatic urothelial carcinoma: results of a large phase 2 study.
Vaughn DJ; Srinivas S; Stadler WM; Pili R; Petrylak D; Sternberg CN; Smith DC; Ringuette S; de Wit E; Pautret V; George C
Cancer; 2009 Sep; 115(18):4110-7. PubMed ID: 19536904
[TBL] [Abstract][Full Text] [Related]
6. Safety and effectiveness of vinflunine in patients with metastatic transitional cell carcinoma of the urothelial tract after failure of one platinum-based systemic therapy in clinical practice.
Castellano D; Puente J; de Velasco G; Chirivella I; López-Criado P; Mohedano N; Fernández O; García-Carbonero I; González MB; Grande E
BMC Cancer; 2014 Oct; 14():779. PubMed ID: 25342282
[TBL] [Abstract][Full Text] [Related]
7. The first Slovak experience with second-line vinflunine in advanced urothelial carcinomas.
Palacka P; Mego M; Obertova J; Chovanec M; Sycova-Mila Z; Mardiak J
Klin Onkol; 2014; 27(6):429-33. PubMed ID: 25493582
[TBL] [Abstract][Full Text] [Related]
8. Long-term survival results of a randomized phase III trial of vinflunine plus best supportive care versus best supportive care alone in advanced urothelial carcinoma patients after failure of platinum-based chemotherapy.
Bellmunt J; Fougeray R; Rosenberg JE; von der Maase H; Schutz FA; Salhi Y; Culine S; Choueiri TK
Ann Oncol; 2013 Jun; 24(6):1466-72. PubMed ID: 23419284
[TBL] [Abstract][Full Text] [Related]
9. Phase I trial of vinflunine and pemetrexed in refractory solid tumors.
Sanoff HK; Davies J; Walko C; Buie L; Chiu WK; Ivanova A; O'Neil B; Stinchcombe TE; Keller K; Dees EC
Invest New Drugs; 2011 Feb; 29(1):131-6. PubMed ID: 19830387
[TBL] [Abstract][Full Text] [Related]
10. Combined treatment with pazopanib and vinflunine in patients with advanced urothelial carcinoma refractory after first-line therapy.
Gerullis H; Eimer C; Ecke TH; Georgas E; Arndt C; Otto T
Anticancer Drugs; 2013 Apr; 24(4):422-5. PubMed ID: 23407060
[TBL] [Abstract][Full Text] [Related]
11. Vinflunine in Advanced Transitional Cell Cancer of the Urothelial Tract: A Potential Option for Maintenance Therapy? A Case Series.
Palumbo R; Licata L; Sottotetti F; Tagliaferri B; Pozzi E; Teragni C; Quaquarini E; Bernardo A
Oncol Res Treat; 2018; 41(1-2):8-13. PubMed ID: 29402855
[TBL] [Abstract][Full Text] [Related]
12. A phase I study of vinflunine in combination with capecitabine in patients with metastatic breast cancer previously treated with anthracyclines and taxanes.
Campone M; Isambert N; Bourbouloux E; Roché H; Bonneterre J; Milano G; Fumoleau P
Cancer Chemother Pharmacol; 2012 Apr; 69(4):871-9. PubMed ID: 22045498
[TBL] [Abstract][Full Text] [Related]
13. The impact of prior platinum therapy on survival in patients with metastatic urothelial cancer receiving vinflunine.
Harshman LC; Fougeray R; Choueiri TK; Schutz FA; Salhi Y; Rosenberg JE; Bellmunt J
Br J Cancer; 2013 Nov; 109(10):2548-53. PubMed ID: 24129239
[TBL] [Abstract][Full Text] [Related]
14. A phase II study of vinflunine in bladder cancer patients progressing after first-line platinum-containing regimen.
Culine S; Theodore C; De Santis M; Bui B; Demkow T; Lorenz J; Rolland F; Delgado FM; Longerey B; James N
Br J Cancer; 2006 May; 94(10):1395-401. PubMed ID: 16622447
[TBL] [Abstract][Full Text] [Related]
15. Safety of Vinflunine in Patients with Advanced Urothelial Carcinoma Refractory to Platinum-based Chemotherapy: A Prospective Pilot Study.
Abdel-Malek R; Shohdy KS; Abbas N; Ismail M; Hamada E; Abdel-Kader Y
Curr Drug Saf; 2019; 14(1):31-36. PubMed ID: 30277164
[TBL] [Abstract][Full Text] [Related]
16. Randomised phase III trial of vinflunine plus capecitabine versus capecitabine alone in patients with advanced breast cancer previously treated with an anthracycline and resistant to taxane.
Martin M; Campone M; Bondarenko I; Sakaeva D; Krishnamurthy S; Roman L; Lebedeva L; Vedovato JC; Aapro M
Ann Oncol; 2018 May; 29(5):1195-1202. PubMed ID: 29447329
[TBL] [Abstract][Full Text] [Related]
17. [First line therapy for local advanced or metastatic urothelial cell carcinoma: randomized phase II study to investigate the combination of vinflunine with gemcitabine and vinflunine with carboplatin in patients unfit for cisplatin therapy with advanced or metastatic urothelial cell carcinoma (JASINT-1 - AB 38/11) of AUO].
Rexer H
Urologe A; 2011 Aug; 50(8):974-6. PubMed ID: 21779884
[No Abstract] [Full Text] [Related]
18. Real-life clinical practice results with vinflunine in patients with relapsed platinum-treated metastatic urothelial carcinoma: an Italian multicenter study (MOVIE-GOIRC 01-2014).
Passalacqua R; Lazzarelli S; Donini M; Montironi R; Tambaro R; De Giorgi U; Pignata S; Palumbo R; Ceresoli GL; Del Conte G; Tonini G; Morelli F; Nolè F; Panni S; Rondini E; Guida A; Zucali PA; Doni L; Iezzi E; Caminiti C
BMC Cancer; 2017 Jul; 17(1):493. PubMed ID: 28724419
[TBL] [Abstract][Full Text] [Related]
19. Second-Line Chemotherapy for Metastatic Urothelial Carcinoma: Importance of Lymph Node-Only Metastasis as a Prognostic Factor and Construction of a Prognostic Model.
Salah S; Lee JL; Rozzi A; Kitamura H; Matsumoto K; Srinivas S; Morales-Barrera R; Carles J; Al-Wardat R; Al-Rabi K; Maakoseh M
Clin Genitourin Cancer; 2016 Jun; 14(3):255-60. PubMed ID: 26552764
[TBL] [Abstract][Full Text] [Related]
20. Second Line Chemotherapy for Advanced and Metastatic Urothelial Carcinoma: Vinflunine and Beyond-A Comprehensive Review of the Current Literature.
Oing C; Rink M; Oechsle K; Seidel C; von Amsberg G; Bokemeyer C
J Urol; 2016 Feb; 195(2):254-63. PubMed ID: 26410730
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
